Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations

Targeted therapy has significantly prolonged survival of non-small cell lung cancer (NSCLC) patients carrying common EGFR mutations, but the standard care for patients with rare mutations has not been well established. Here, we report a 65-year-old female diagnosed with stage IIIC lung adenocarcinom...

Full description

Saved in:
Bibliographic Details
Main Authors: Yueming He, Yitao Wu, Rongqi He, Meng Xu, Heshan Chen, Yiran Meng, Liuqing Zheng, Li Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Pharmacology
Subjects:
non-small cell lung cancer
rare mutations
EGFR L858M/L861R
afatinib
anlotinib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1437086/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items